Digital therapeutics are going from strength to strength during the pandemic.
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
Licensing deal could enable bundling of antipsychotics with management technology.
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.